OncoMatch/Clinical Trials/NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Is NCT04494503 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including APG-2575 and Rituximab for chronic lymphocytic leukemia.
Treatment: APG-2575 · Rituximab · Ibrutinib — The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 24 months
Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy within 24 months
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 months
autologous hematopoietic stem cell transplantation within 12 months
Cannot have received: adoptive cell immunotherapy
Exception: within 24 months
adoptive cell immunotherapy within 24 months
Cannot have received: monoclonal antibody therapy against CLL
Exception: within 4 weeks prior to the first dose of the study drug
Monoclonal antibody therapy against CLL was adopted within 4 weeks prior to the first dose of the study drug.
Cannot have received: anti-tumor therapies (chemotherapy, radiotherapy, anti-tumor steroid treatment, anti-tumor Chinese medicine treatment)
Exception: within 14 days or 5x half-life before the first dose of study drug
Receive any of the following treatments within 14 days or 5x half-life before the first dose of study drug, or clinically significant adverse reactions / toxicities due to previous treatments have not recovered to ≤ Grade 1: Anti-tumor therapies include chemotherapy, radiotherapy, anti-tumor steroid treatment, anti-tumor Chinese medicine treatment
Cannot have received: investigational treatment (including targeted small molecule drugs)
Exception: within 14 days or 5x half-life before the first dose of study drug
investigational treatment, including targeted small molecule drugs
Cannot have received: BCL2 inhibitor
Received Bcl-2 inhibitor treatment.
Lab requirements
Blood counts
Adequate bone marrow function independent of growth factor and transfusion
Kidney function
Adequate renal function
Liver function
Adequate liver function
Cardiac function
QTcF interval ≤450ms in males, and ≤470ms in females; Cardiovascular disease of grade ≥2 (New York Heart Association Class) excluded
QTcF interval ≤450ms in males, and ≤470ms in females. Adequate bone marrow function independent of growth factor and transfusion. Adequate renal and liver function. Cardiovascular disease of grade ≥2 (New York Heart Association Class) excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04494503 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, adoptive cell immunotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages